{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:46Z","timestamp":1789477546228,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National key research and development plan","award":["Nos. 2024YFC3406705"],"award-info":[{"award-number":["Nos. 2024YFC3406705"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["Nos. 2023YC19"],"award-info":[{"award-number":["Nos. 2023YC19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12519-026-01065-y","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:51:31Z","timestamp":1788497491000},"page":"793-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome: a retrospective cohort study"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6046-6763","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Yun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/epi.14016","volume":"59","author":"LJ Hirsch","year":"2018","unstructured":"Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59:739\u201344.https:\/\/doi.org\/10.1111\/epi.14016.","journal-title":"Epilepsia"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1111\/epi.17391","volume":"63","author":"R Wickstrom","year":"2022","unstructured":"Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): summary and clinical tools. Epilepsia. 2022;63:2827\u201339.\u00a0https:\/\/doi.org\/10.1111\/epi.17391","journal-title":"Epilepsia"},{"issue":"1","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/epi4.12447","volume":"6","author":"S Koh","year":"2021","unstructured":"Koh S, Wirrell E, Vezzani A, Nabbout R, Muscal E, Kaliakatsos M, et al. Proposal to optimize evaluation and treatment of febrile infection-related epilepsy syndrome (FIRES): a report from FIRES workshop. Epilepsia Open. 2021;6:62\u201372.\u00a0https:\/\/doi.org\/10.1002\/epi4.12447.","journal-title":"Epilepsia Open"},{"issue":"1","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1474-4422(10)70214-3","volume":"10","author":"R Nabbout","year":"2011","unstructured":"Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011;10:99\u2013108.\u00a0https:\/\/doi.org\/10.1016\/s1474-4422(10)70214-3.","journal-title":"Lancet Neurol"},{"issue":"Suppl 8","key":"1065_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1528-1167.2011.03230.x","volume":"52","author":"U Kramer","year":"2011","unstructured":"Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, et al. Febrile infection-related epilepsy syndrome (FIRES): does duration of anesthesia affect outcome? Epilepsia. 2011;52:28\u201330.\u00a0https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03230.x.","journal-title":"Epilepsia"},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.seizure.2022.06.012","volume":"100","author":"A Aledo-Serrano","year":"2022","unstructured":"Aledo-Serrano A, Hariramani R, Gonzalez-Martinez A, \u00c1lvarez-Troncoso J, Toledano R, Bayat A, et al. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): effectiveness and safety from a case-series. Seizure. 2022;100:51\u20135.\u00a0https:\/\/doi.org\/10.1016\/j.seizure.2022.06.012.","journal-title":"Seizure"},{"issue":"1","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0036-1597271","volume":"48","author":"A van Baalen","year":"2017","unstructured":"van Baalen A, Vezzani A, H\u00e4usler M, Kluger G. Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis. Neuropediatrics. 2017;48:5\u201318.\u00a0https:\/\/doi.org\/10.1055\/s-0036-1597271.","journal-title":"Neuropediatrics"},{"issue":"11","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/j.1528-1167.2011.03250.x","volume":"52","author":"U Kramer","year":"2011","unstructured":"Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52:1956\u201365.\u00a0https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03250.x.","journal-title":"Epilepsia"},{"issue":"8","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/epi.16275","volume":"60","author":"K Kothur","year":"2019","unstructured":"Kothur K, Bandodkar S, Wienholt L, Chu S, Pope A, Gill D, et al. Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus. Epilepsia. 2019;60:1678\u201388.\u00a0\u00a0https:\/\/doi.org\/10.1111\/epi.16275.","journal-title":"Epilepsia"},{"issue":"1","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.26627","volume":"94","author":"A Hanin","year":"2023","unstructured":"Hanin A, Cespedes J, Dorgham K, Pulluru Y, Gopaul M, Gorochov G, et al. Cytokines in new-onset refractory status epilepticus predict outcomes. Ann Neurol. 2023;94:75\u201390.\u00a0https:\/\/doi.org\/10.1002\/ana.26627.","journal-title":"Ann Neurol"},{"issue":"6","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.25374","volume":"84","author":"JS Jun","year":"2018","unstructured":"Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84:940\u20135.\u00a0https:\/\/doi.org\/10.1002\/ana.25374.","journal-title":"Ann Neurol"},{"issue":"11","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3760\/cma.j.cn113694-20220322-00221","volume":"55","author":"W Ying","year":"2022","unstructured":"Wang Y, Ma YL, Wang Y, Zhang J, Liu M, Li XL, et al. A case of febrile infection-related epilepsy syndrome in children successfully treated with tocilizumab and literature review. Chin J Neurol. 2022;55:1277-85. https:\/\/doi.org\/10.3760\/cma.j.cn113694-20220322-00221(in Chinese).","journal-title":"Chin J Neurol"},{"issue":"6","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1111\/epi.17591","volume":"64","author":"ML Girardin","year":"2023","unstructured":"Girardin ML, Flamand T, Roignot O, Abi Warde MT, Mutschler V, Voulleminot P, et al. Treatment of new onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia. 2023;64:e87\u201392.\u00a0https:\/\/doi.org\/10.1111\/epi.17591.","journal-title":"Epilepsia"},{"key":"1065_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/2329048X20979253","volume":"7","author":"CM Stredny","year":"2020","unstructured":"Stredny CM, Case S, Sansevere AJ, Son M, Henderson L, Gorman MP. Interleukin-6 blockade with Tocilizumab in Anakinra-refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). Child Neurology Open. 2020;7:2329048x20979253.\u00a0https:\/\/doi.org\/10.1177\/2329048X20979253.","journal-title":"Child Neurology Open"},{"issue":"6","key":"1065_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5952","volume":"10","author":"T Kurimoto","year":"2022","unstructured":"Kurimoto T, Matsuoka T, Ami Y, Kanno K, Fujii T, Fujiwara N, et al. Anti-inflammatory and immune-mediated therapy for a case of febrile infection-related epilepsy syndrome with rapid recurrence. Clin Case Rep. 2022;10:e5952.\u00a0https:\/\/doi.org\/10.1002\/ccr3.5952.","journal-title":"Clin Case Rep"},{"issue":"24","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1212\/WNL.0000000000207068","volume":"100","author":"Y Goh","year":"2023","unstructured":"Goh Y, Tay SH, Yeo LLL, Rathakrishnan R. Bridging the gap: tailoring an approach to treatment in febrile infection-related epilepsy syndrome. Neurology. 2023;100:1151\u20135.https:\/\/doi.org\/10.1212\/WNL.0000000000207068.","journal-title":"Neurology"},{"key":"1065_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577142","volume":"340","author":"V Cantar\u00edn-Extremera","year":"2020","unstructured":"Cantar\u00edn-Extremera V, Jim\u00e9nez-Legido M, Duat-Rodr\u00edguez A, Garc\u00eda-Fern\u00e1ndez M, Ortiz-Cabrera NV, Ruiz-Falc\u00f3-Rojas ML, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: experience in two pediatric patients. J Neuroimmunol. 2020;340:577142.\u00a0https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577142.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1535759719835363","volume":"19","author":"N Gaspard","year":"2019","unstructured":"Gaspard N. A new hose to extinguish the FIRES? Epilepsy Curr. 2019;19:86\u20137.\u00a0https:\/\/doi.org\/10.1177\/1535759719835363.","journal-title":"Epilepsy Curr"},{"key":"1065_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578298","volume":"388","author":"AM Alaskar","year":"2024","unstructured":"Alaskar AM, Aljohani MA, Dionisio S, Asiry MA, Alqadi K. Time to FIRE NORSE: a single acronym for a heterogeneous presentation. Further information from a case series and discussion of the literature. J Neuroimmunol. 2024;388:578298.\u00a0https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578298.","journal-title":"J Neuroimmunol"},{"key":"1065_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.yebeh.2019.02.033","volume":"95","author":"SK Lam","year":"2019","unstructured":"Lam SK, Lu WY, Weng WC, Fan PC, Lee WT. The short-term and long-term outcome of febrile infection-related epilepsy syndrome in children. Epilepsy Behav. 2019;95:117\u201323.\u00a0https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.033.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1065_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/epi4.12317","volume":"4","author":"R Dilena","year":"2019","unstructured":"Dilena R, Mauri E, Aronica E, Bernasconi P, Bana C, Cappelletti C, et al. Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. Epilepsia Open. 2019;4:344\u201350. https:\/\/doi.org\/10.1002\/epi4.12317.","journal-title":"Epilepsia Open"},{"key":"1065_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577789","volume":"363","author":"T Wadayama","year":"2022","unstructured":"Wadayama T, Shimizu M, Yata T, Ishikura T, Kajiyama Y, Hirozawa D, et al. Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment. J Neuroimmunol. 2022;363:577789.\u00a0https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577789.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"1065_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/epi.17933","volume":"65","author":"A Hanin","year":"2024","unstructured":"Hanin A, Muscal E, Hirsch LJ. Second-line immunotherapy in new onset refractory status epilepticus. Epilepsia. 2024;65:1203\u201323.\u00a0https:\/\/doi.org\/10.1111\/epi.17933.","journal-title":"Epilepsia"},{"issue":"1","key":"1065_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.mcna.2023.05.020","volume":"108","author":"R Carson","year":"2024","unstructured":"Carson R, Stredny CM. Severe, refractory seizures: new-onset refractory status epilepticus and febrile infection-related epilepsy syndrome. Med Clin North Am. 2024;108:201\u201313.\u00a0https:\/\/doi.org\/10.1016\/j.mcna.2023.05.020.","journal-title":"Med Clin North Am"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01065-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:20:56Z","timestamp":1789474856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01065-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01065-y","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Yu-Wu Jiang is a member of the Editorial Board for\n                      World Journal of Pediatrics\n                      . The paper was handled by a non-conflicted editor and has undergone rigorous peer review. Author Yu-Wu Jiang was not involved in either the review process or the decisions related to this manuscript. All other authors have declared to have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Biomedical Research Ethics Committee of Peking University First Hospital (approval No. 2024 Yan 217-002).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}